Compare VTAK & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTAK | INM |
|---|---|---|
| Founded | 2002 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.7M |
| IPO Year | 2018 | 2020 |
| Metric | VTAK | INM |
|---|---|---|
| Price | $0.91 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.5K | 76.0K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $442,000.00 | ★ $4,942,633.00 |
| Revenue This Year | $1,170.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3057.14 | 7.50 |
| 52 Week Low | $0.15 | $0.58 |
| 52 Week High | $4.31 | $7.98 |
| Indicator | VTAK | INM |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 44.77 |
| Support Level | $0.15 | $0.58 |
| Resistance Level | $1.28 | $0.94 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 24.40 | 82.90 |
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.